Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Predicted levels of HIV drug resistance : potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. / Cambiano, Valentina; Bertagnolio, Silvia; Jordan, Michael R; Pillay, Deenan; Perriëns, Joseph H; Venter, Francois; Lundgren, Jens; Phillips, Andrew.
In: AIDS, Vol. 28 Suppl 1, 2014, p. S15-23.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Predicted levels of HIV drug resistance
T2 - potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation
AU - Cambiano, Valentina
AU - Bertagnolio, Silvia
AU - Jordan, Michael R
AU - Pillay, Deenan
AU - Perriëns, Joseph H
AU - Venter, Francois
AU - Lundgren, Jens
AU - Phillips, Andrew
PY - 2014
Y1 - 2014
N2 - BACKGROUND: There is concern that the expansion of antiretroviral roll-out may impact future drug resistance levels and hence compromise the benefits of antiretroviral therapy (ART) at an individual and population level. We aimed to predict future drug resistance in South Africa and its long-term effects.METHODS: The previously validated HIV Synthesis model was calibrated to South Africa. Resistance was modeled at the level of single mutations, transmission potential, persistence, and effect on drug activity.RESULTS: We estimate 652 000 people (90% uncertainty range: 543 000-744 000) are living with nonnucleoside reverse transcriptase inhibitor (NNRTIs)-resistant virus in South Africa, 275 000 in majority virus [Non-nucleoside reverse transcriptase inhibitor resistant virus present in majority virus (NRMV)] with an unsuppressed viral load. If current diagnosis and retention in care and eligibility criteria are maintained, in 20 years' time HIV incidence is projected to have declined by 22% (95% confidence interval, CI -23 to -21%), and the number of people carrying NNRTI resistance to be 2.9-fold higher. If enhancements in diagnosis and retention in care occur, and ART is initiated at CD4 cell count less than 500 cells/μl, HIV incidence is projected to decline by 36% (95% CI: -37 to -36%) and the number of people with NNRTI resistance to be 4.1-fold higher than currently. Prevalence of people with viral load more than 500 copies/ml carrying NRMV is not projected to differ markedly according to future ART initiation policy, given the current level of diagnosis and retention are maintained.CONCLUSION: Prevalence of resistance is projected to increase substantially. However, introduction of policies to increase ART coverage is not expected to lead to appreciably higher prevalence of HIV-positive people with resistance and viral load more than 500 copies/ml. Concern over resistance should not stop expansion of treatment availability.
AB - BACKGROUND: There is concern that the expansion of antiretroviral roll-out may impact future drug resistance levels and hence compromise the benefits of antiretroviral therapy (ART) at an individual and population level. We aimed to predict future drug resistance in South Africa and its long-term effects.METHODS: The previously validated HIV Synthesis model was calibrated to South Africa. Resistance was modeled at the level of single mutations, transmission potential, persistence, and effect on drug activity.RESULTS: We estimate 652 000 people (90% uncertainty range: 543 000-744 000) are living with nonnucleoside reverse transcriptase inhibitor (NNRTIs)-resistant virus in South Africa, 275 000 in majority virus [Non-nucleoside reverse transcriptase inhibitor resistant virus present in majority virus (NRMV)] with an unsuppressed viral load. If current diagnosis and retention in care and eligibility criteria are maintained, in 20 years' time HIV incidence is projected to have declined by 22% (95% confidence interval, CI -23 to -21%), and the number of people carrying NNRTI resistance to be 2.9-fold higher. If enhancements in diagnosis and retention in care occur, and ART is initiated at CD4 cell count less than 500 cells/μl, HIV incidence is projected to decline by 36% (95% CI: -37 to -36%) and the number of people with NNRTI resistance to be 4.1-fold higher than currently. Prevalence of people with viral load more than 500 copies/ml carrying NRMV is not projected to differ markedly according to future ART initiation policy, given the current level of diagnosis and retention are maintained.CONCLUSION: Prevalence of resistance is projected to increase substantially. However, introduction of policies to increase ART coverage is not expected to lead to appreciably higher prevalence of HIV-positive people with resistance and viral load more than 500 copies/ml. Concern over resistance should not stop expansion of treatment availability.
KW - Adolescent
KW - Adult
KW - Aged
KW - Anti-Retroviral Agents
KW - Antiretroviral Therapy, Highly Active
KW - Drug Resistance, Viral
KW - Drug Utilization
KW - Female
KW - HIV Infections
KW - Humans
KW - Male
KW - Middle Aged
KW - Models, Theoretical
KW - Prevalence
KW - South Africa
KW - Young Adult
U2 - 10.1097/QAD.0000000000000082
DO - 10.1097/QAD.0000000000000082
M3 - Journal article
C2 - 24468943
VL - 28 Suppl 1
SP - S15-23
JO - AIDS
JF - AIDS
SN - 1350-2840
ER -
ID: 137313513